Beijing Tong Ren Tang Chinese Medicine (SEHK:3613) - Aandelenkoers, Nieuws & Analyse

3613 Overzicht aandelen

Beijing Tong Ren Tang Chinese Medicine Company Limited houdt zich, samen met haar dochterondernemingen, bezig met de productie van, detailhandel in en groothandel in gezondheidsproducten en Chinese medicijnen aan groothandelaren en particulieren.

Over het bedrijf

3613 fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	3/6
Prestaties in het verleden	1/6
Financiële gezondheid	5/6
Dividenden	4/6

Beloningen

Verhandeld tegen 17% onder onze schatting van de reële waarde

De winst zal naar verwachting met 16.51% per jaar groeien

Risicoanalyse

Hoog niveau van niet-contante inkomsten

Dividend van 3.96% wordt niet goed gedekt door vrije kasstromen

Beijing Tong Ren Tang Chinese Medicine Company Limited Concurrenten

Tong Ren Tang Technologies

SEHK:1666

HK$6.7b

Consun Pharmaceutical Group

SEHK:1681

HK$6.7b

China Shineway Pharmaceutical Group

SEHK:2877

HK$7.0b

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd

SEHK:1349

HK$7.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Beijing Tong Ren Tang Chinese Medicine
Historische aandelenkoersen
Huidige aandelenkoers	HK$8.34
52 Week Hoogtepunt	HK$13.44
52 Week Laag	HK$7.03
Bèta	0.41
11 maand verandering	-12.85%
3 maanden verandering	-5.76%
1 Jaar Verandering	-31.64%
33 jaar verandering	-23.35%
5 jaar verandering	-23.35%
Verandering sinds IPO	27.72%

Recent nieuws en updates

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up

Oct 04

Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders

Sep 06

Is There An Opportunity With Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 31% Undervaluation?

Sep 02

Recent updates

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up

Oct 04

Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders

Sep 06

Is There An Opportunity With Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 31% Undervaluation?

Sep 02

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk

Feb 05

Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Jan 03

A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Sep 28

Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today

Jul 12

Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?

Mar 29

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28

Apr 28

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28

Mar 25

Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?

Oct 27

Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 28

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Mar 11

What Type Of Returns Would Beijing Tong Ren Tang Chinese Medicine's(HKG:3613) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Feb 04

Should Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Be Part Of Your Dividend Portfolio?

Jan 18

Could The Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Ownership Structure Tell Us Something Useful?

Dec 29

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Dec 11

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Nov 23

Rendement voor aandeelhouders

	3613	HK Pharmaceuticals	HK Markt
7D	-1.0%	-7.2%	-0.6%
1Y	-31.6%	-5.9%	14.2%

Rendement versus industrie: 3613 presteerde slechter dan de Hong Kong Pharmaceuticals -sector, die het afgelopen jaar een rendement van -5.9 % opleverde.

Rendement versus markt: 3613 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 14.2 % opleverde.

Prijsvolatiliteit

Is 3613's price volatile compared to industry and market?
3613 volatility
3613 Average Weekly Movement	6.7%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.2%

Stabiele aandelenkoers: 3613 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van 3613 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1669	779	Wang Chi	www.tongrentangcm.com

Beijing Tong Ren Tang Chinese Medicine Company Limited houdt zich, samen met haar dochterondernemingen, bezig met de productie, detailhandel en groothandel van gezondheidsproducten en Chinese medicijnen aan groothandelaren en particulieren. Het bedrijf is actief in drie segmenten: Hong Kong, het Chinese vasteland en overzeese gebieden. Het biedt ook Chinese medische consultatie- en behandelingsdiensten aan.

Beijing Tong Ren Tang Chinese Medicine Company Limited Samenvatting

Hoe verhouden de winst en inkomsten van Beijing Tong Ren Tang Chinese Medicine zich tot de beurswaarde?
3613 fundamentele statistieken
Marktkapitalisatie	HK$6.89b
Inkomsten(TTM)	HK$494.14m
Inkomsten(TTM)	HK$1.38b

14.1x

Koers/Winstverhouding

5.1x

P/S-verhouding

Is 3613 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
3613 resultatenrekening (TTM)
Inkomsten	HK$1.38b
Kosten van inkomsten	HK$384.69m
Brutowinst	HK$991.96m
Overige uitgaven	HK$497.83m
Inkomsten	HK$494.14m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.59
Brutomarge	72.06%
Nettowinstmarge	35.89%
Schuld/Eigen Vermogen Verhouding	0.006%

Hoe presteerde 3613 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

4.0%

Huidig dividendrendement

56%

Uitbetalingsratio

3613 Overzicht aandelen

Beloningen

Risicoanalyse

Beijing Tong Ren Tang Chinese Medicine Company Limited Concurrenten

SEHK:1666

HK$6.7b

SEHK:1681

HK$6.7b

SEHK:2877

HK$7.0b

SEHK:1349

HK$7.8b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Now 20% undervalued after recent price drop

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 22%

Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders

First half 2024 earnings released: EPS: HK$0.26 (vs HK$0.32 in 1H 2023)

Is There An Opportunity With Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 31% Undervaluation?

Recent updates

Now 20% undervalued after recent price drop

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Shares Climb 32% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 22%

Earnings Troubles May Signal Larger Issues for Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Shareholders

First half 2024 earnings released: EPS: HK$0.26 (vs HK$0.32 in 1H 2023)

Is There An Opportunity With Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 31% Undervaluation?

New major risk - Earnings quality

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2024 Results on Aug 30, 2024

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended December 31, 2023

Now 22% overvalued after recent price rise

Upcoming dividend of HK$0.33 per share

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Wang Chi as an Executive Director and a Member of the Competition Executive Committee

Now 21% overvalued after recent price rise

Full year 2023 earnings: EPS and revenues miss analyst expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces CEO Changes

Beijing Tong Ren Tang Chinese Medicine Company Limited, Annual General Meeting, May 31, 2024

New minor risk - Financial data availability

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk

Price target decreased by 14% to HK$14.93

Investor sentiment deteriorates as stock falls 16%

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2023 Results on Mar 31, 2024

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Gu Hai Ou as Executive Director, Chairman of Board and Authorised Representative

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Nine Months, 2023 Results on Oct 31, 2023

A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Resignation of Lin Man as Executive Director, Chief Operating Officer, Member of Competition Executive Committee

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Retirement of Ding Yong Ling as Executive Director and Chairman of the Board

First half 2023 earnings released: EPS: HK$0.32 (vs HK$0.26 in 1H 2022)

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2023 Results on Aug 10, 2023

Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.33 per share at 2.1% yield

Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?

Price target increased by 8.0% to HK$14.66

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Nine Months, 2022 Results on Oct 31, 2022

Upcoming dividend of HK$0.25 per share

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Special Interim Dividend, Payable on 21 October 2022

High number of new directors

COO & Executive Director recently bought HK$183k worth of stock

Price target decreased to HK$13.57

First half 2022 earnings released

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Feng Li as Executive Director

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2022 Results on Aug 12, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.28 per share

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Final Dividend for the Year Ended 31 December 2021

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2021 Results on Mar 07, 2022

Investor sentiment improved over the past week

CEO & Executive Director recently bought HK$178k worth of stock

Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?